Suggested remit: To appraise the clinical and cost effectiveness of gefapixant within its marketing authorisation for treating refractory or unexplained chronic cough.
Status Proposed
Process STA 2018
ID number 3789

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
13 May 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
20 April 2021 (14:00) Scoping workshop
01 March 2021 - 29 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance